Deucravacitinib in PG

NCT05821374 | Withdrawn Early Phase 1 FDA Drug

• 1 other identifier: STUDY02001753
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).

Conditions

Pyoderma Gangrenosum

Outcome Measures

Primary Outcomes (2)

• Change in Physician's Global Assessment (PGA)

  PGA will be used for overall assessment of efficacy.

  Baseline; Days 8, 15, 29, 57, and 85; Follow up Day 115

• Change from baseline in ulcer size measured by calculating the area of the ulcers in centimeters squared using a digital application.

  imitoAG application for mobile devices will be used to calculate the dimensions of the ulcers in centimeters to determine if the size of the ulcers is changed by the treatment.

  Baseline; Days 8, 15, 29, 57, and 85; Follow up Day 115

Secondary Outcomes (1)

• The percentage of patients needing rescue therapy from baseline to Day 115

  Baseline through Day 115

Study Arms (1)

Deucravacitinib

EXPERIMENTAL

Participants to receive Deucravacitinib 6 mg tablets orally twice daily for 12 weeks.

Drug: Deucravacitinib

Interventions

Deucravacitinib DRUG

6 mg tablet

Also known as: SOTYKTU

Deucravacitinib

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men and women between the ages of 18-70 years old
• Diagnosed with pyoderma gangrenosum requiring one major and at least 4 minor criteria
• Women must not be pregnant, lactating, or planning pregnancy during the study period
• Women of child-bearing potential must be on birth control for the duration of the treatment period.
• Subjects must agree to the use of at least one of the following contraception methods for the entire duration of the study until at least 30 days after taking their last dose of study drug:
• Women: Hormonal contraception (oral, injections, patch, implant, or vaginal-ring); Spiral (with or without hormones); any sterilization methods; a partner who has had a vasectomy; or sexual abstinence.
• Other acceptable methods of contraception are male or female condoms (with or without spermicide) or a cap, diaphragm, or sponge with spermicide.
• Willing to discontinue topical and/or systemic therapies, with the exception of oral rescue therapy with steroids.
• The wash period for systemic therapies will largely depend on the specific treatment but, in general, will be at least 6 months for biologics and 3 months for other immune- suppressants such as cyclosporine, mycophenolate mofetil, methotrexate, etc. No wash out period is required for topicals.
• Capable and willing to sign Institutional Review Board/IEC-approved written informed consent form in accordance with regulatory and institutional guidelines before the performance of any protocol-related procedures.

You may not qualify if:

• Patient under 18 years of age.
• Patients with a history of inflammatory bowel disease.
• Patients on systemic immunosuppressive/immune modulating therapy including: oral steroids, cyclosporine, mycophenolate mofetil, methotrexate, Azathioprine or TNFα inhibitor at time of starting deucravacitinib.
• Patients currently enrolled in another investigational study.
• Patients with a history or evidence of active infection and/or febrile illness within 7 days; or serious infection requiring antibiotic treatment within 30 days
• Hepatitis C virus (HCV): subjects known to be positive for anti-HCV antibody or for HCV RNA detectable by polymerase chain reaction (PCR)
• Hepatitis B virus (HBV): subjects known to be positive for hepatitis B surface antigen or for HBV DNA detectable by PCR
• Human Immunodeficiency Virus (HIV) infection: subjects known to be HIV positive
• History of active or inadequately treated latent tuberculosis (TB)
• Known or suspected systemic or skin autoimmune disorder other than pyoderma gangrenosum
• Any unstable major illness or evidence of unstable condition of major organ systems including psychiatric
• Cancer or history of lymphoproliferative disease within last 5 years; exception is cutaneous basal cell carcinoma or squamous cell carcinoma that has been treated.
• Major surgery within the last 4 weeks
• Live vaccines within the last 60 days
• Leukopenia (absolute WBC count \< 3000/mm3); Lymphopenia (ALC \< 500/mm3); Neutropenia (ANC \< 1000/mm3)

Sponsors & Collaborators

• Dartmouth-Hitchcock Medical Center: lead
• Bristol-Myers Squibb: collaborator

Study Sites (1)

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, 03576, United States

Location

MeSH Terms

Conditions

Pyoderma Gangrenosum

Interventions

deucravacitinib

Condition Hierarchy (Ancestors)

Pyoderma; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Vascular; Skin Ulcer

Study Officials

• Brian J. Simmons, MD

  Dartmouth-Hitchcock Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of Dermatology Research

Study Record Dates

• First Submitted: March 20, 2023
• First Posted: April 20, 2023
• Study Start: April 29, 2024
• Primary Completion: April 29, 2024
• Study Completion: April 29, 2024
• Last Updated: June 27, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)